How Do Semaglutide Side-Chain Intermediates Differ? CAS 1662688-20-1 vs 1118767-16-0 vs 1169630-40-3

2026.09.04

When researching Semaglutide side-chain intermediates, CAS 1662688-20-1, 1118767-16-0 and 1169630-40-3 often appear in the same product category. All three are associated with the lipid side-chain architecture used in Semaglutide-related peptide synthesis, but they are not different names for the same compound.

The main difference is how far each material has progressed through side-chain assembly and how it enters the next stage of the process. Some routes use a lysine building block that already carries the lipid side chain, while others begin with a separate protected side-chain fragment and introduce it through a later activation or coupling step.

For R&D, process-development and sourcing teams, this distinction is more useful than comparing CAS numbers, purity values or quotations alone. The first question is whether the selected route requires a preassembled lysine building block, a protected side-chain fragment or an activated intermediate for downstream coupling.

The Three Intermediates Represent Different Structural Stages

The differences become much clearer when the three materials are compared by structural state.

All three contain structural elements associated with the Semaglutide lipid side chain, including the long-chain fatty-acid segment, γ-Glu and AEEA units. What differs is the degree of assembly and the way each intermediate is intended to enter the next synthetic step.

This is also why “Semaglutide side chain” is too broad to serve as a technical purchasing description on its own. For sourcing purposes, the exact CAS number, chemical structure, protection state and activation state should be confirmed together.

CAS 1662688-20-1: A More Highly Preassembled Side-Chain Building Block

CAS 1662688-20-1 is commonly identified as:Fmoc-L-Lys[Oct-(OtBu)-Glu-(OtBu)-AEEA-AEEA]-OH

Its defining feature is that lysine is already part of the complete intermediate structure. The AEEA linker units, γ-Glu and the long-chain lipid segment have already been assembled onto an Fmoc-protected lysine residue.

The structure can be viewed in simplified form as:Fmoc-Lys → AEEA-AEEA → γ-Glu → C18 lipid segment

This makes Semaglutide intermediate 1662688-20-1, Semaglutide lysine side-chain intermediate and preassembled lipidated lysine building block relevant search terms for this material.

From a process perspective, 1662688-20-1 is better understood as a preassembled lipidated lysine building block rather than simply as a fatty-acid side chain. Whether lysine is already incorporated into the intermediate is one of the key points that separates this material from the other two structures discussed below.

CAS 1118767-16-0: The Side-Chain Framework Is Present, but Fmoc-Lys Is Not

A Protected Fatty-Acid Side-Chain Fragment

CAS 1118767-16-0 is commonly written as:tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu

This material already contains the main structural elements of the lipid side chain, including the C18 chain, γ-Glu and AEEA-AEEA linker segment. Unlike CAS 1662688-20-1, however, it remains a separate side-chain fragment and does not yet contain Fmoc-Lys.

For that reason, it fits more naturally within the category of Semaglutide fatty-acid side-chain intermediate. The core side-chain framework has already been assembled, but the material may still require further activation, coupling or structural transformation depending on the selected route.

This is why 1118767-16-0 and 1662688-20-1 are often compared even though they do not represent the same level of assembly. Their structural elements are related, but their positions in the process are different.

CAS 1169630-40-3: An Activated Side Chain for a Later Coupling Step

The OSu Group Changes Its Role in the Process

CAS 1169630-40-3 is commonly identified as:Ste-γ-Glu-AEEA-AEEA-OSu

Compared with 1118767-16-0, the most important difference is the activated terminal group. The presence of an OSu group places this material at a different stage of the synthesis sequence.

Rather than functioning only as a protected upstream fragment, it is better described as a Semaglutide activated side-chain intermediate intended for a subsequent coupling step.

In routes where a suitable peptide intermediate is prepared first and the lipid side chain is introduced later, this activated form serves a different purpose from the preassembled Fmoc-Lys strategy represented by CAS 1662688-20-1. One approach brings the side chain into the process at the lysine-building-block stage, while the other introduces the activated side chain at a later point.

What Is the Main Difference Between CAS 1662688-20-1 and 1118767-16-0?

These two materials are often compared because both contain AEEA, γ-Glu and C18 lipid-related structural elements. Their names and side-chain architecture can also look similar at first glance.

The most practical difference is straightforward: CAS 1662688-20-1 already contains Fmoc-Lys, while CAS 1118767-16-0 does not.

In CAS 1662688-20-1, the lipid side chain has already been assembled onto Fmoc-Lys, making the material closer to a complete lysine building block. CAS 1118767-16-0 remains a separate protected side-chain fragment that still has to be integrated into the selected process.

For this reason, searches around 1662688-20-1 vs 1118767-16-0 are usually less about which material has the higher headline purity or lower price, and more about whether lysine needs to be part of the intermediate at that stage of the route.

Once that requirement is clear, the role of each material becomes much easier to assess.

Placing the Three CAS Numbers Back into the Synthesis Route

The chemical names can look complicated when viewed in isolation. Their roles become clearer once they are considered within the overall process.

662688-20-1: Preassembled Lipidated Lysine Building Block

In CAS 1662688-20-1, the lipid side chain is already attached to Fmoc-Lys. Lysine is therefore part of the intermediate rather than a separate downstream component.

The material is best described as a:

preassembled lipidated lysine building block

1118767-16-0: Protected Side-Chain Fragment

CAS 1118767-16-0 already contains the C18–γ-Glu–AEEA-AEEA framework, but it remains an independent protected side chain.

Its most accurate positioning is:

protected fatty-acid side-chain fragment

Whether further activation or a specific coupling step is required depends on the process design.

1169630-40-3: Activated Side-Chain Intermediate

CAS 1169630-40-3 contains an OSu-activated group and is therefore closer to the downstream coupling stage than a protected side-chain fragment.

It is best described as an:

activated side-chain intermediate

These materials should not be presented as a fixed “1 → 2 → 3” sequence. They represent different structural states within different synthesis strategies.

One route may follow:protected side-chain fragment → activation → side-chain coupling

Another may use:side chain preassembled on Fmoc-Lys → incorporation as a lysine building block during peptide assembly

This framework is more useful than treating the three CAS numbers as directly interchangeable materials.

C18 Long-Chain Structure and Related Building Blocks

The long-chain portion of the Semaglutide lipid side chain is associated with C18 dicarboxylic-acid chemistry. Within related intermediate systems, Octadecanedioic Acid Mono-tert-butyl Ester (CAS 843666-40-0) is a mono-protected long-chain dicarboxylic-acid derivative used as a building block for related long-chain side-chain structures.

This link gives readers additional context on C18 dicarboxylic-acid building blocks and connects related technical content within the Juntai website. CAS 843666-40-0 should not be presented as an equivalent substitute for CAS 1662688-20-1, as the two materials represent different structural stages.

What Should Be Confirmed Before Sourcing Semaglutide Side-Chain Intermediates?

For structurally complex Semaglutide intermediates, starting with price or a single purity figure can overlook the more important question of whether the material actually matches the intended synthesis route.

A more practical evaluation begins with structure and process role. Once those points are clear, quality and supply conditions can be assessed in the proper context.

1.Confirm the Exact CAS Number and Chemical Structure

“Semaglutide side chain” is useful as a broad product-category term, but it is not specific enough for technical sourcing. The same commercial description may refer to several CAS numbers representing different stages of side-chain assembly.

The CAS number, full chemical name and structure should be confirmed before the material is evaluated further.

2.Confirm Whether Fmoc-Lys Is Already Included

This is particularly important when comparing CAS 1662688-20-1 with separate side-chain intermediates.

If Fmoc-Lys is already part of the molecule, the intermediate has undergone a greater degree of preassembly and occupies a different position in the synthesis route. That difference directly affects how the material should be evaluated for a specific process.

3.Check the Protection and Activation State

A protected side-chain fragment and an OSu-activated intermediate are intended for different downstream operations. Although both may appear under the same broad “side-chain intermediate” category, their process roles are not the same.

This point should be confirmed with the R&D or process team before sample evaluation or sourcing decisions are made.

4.Then Compare Quality and Supply Requirements

Once the structural role has been confirmed, the next step is to review the relevant specification and supply conditions.

Typical items may include assay, purity, identification, storage conditions, packaging, lead time and batch documentation. For intermediates at different structural stages, a single purity figure should not be used as the sole basis for comparison.

Route compatibility comes first. Quality and supply parameters should then be evaluated within that context.

Conclusion: Compare Structural Stage, Not Just CAS Numbers

CAS 1662688-20-1, 1118767-16-0 and 1169630-40-3 are all associated with Semaglutide side-chain intermediates, but they represent different structural stages.

CAS 1662688-20-1 already contains the lipid side chain attached to Fmoc-Lys and is best understood as a preassembled lipidated lysine building block. CAS 1118767-16-0 is a separate protected C18–γ-Glu–AEEA-AEEA side-chain fragment, while CAS 1169630-40-3 contains an OSu-activated group and is more closely associated with downstream coupling.

For process-development and sourcing teams, the most useful question is not which material is universally “better,” but which structural state matches the selected synthesis route. Once the CAS number, assembly level, protection state and downstream reaction step are clear, specification, COA and supply conditions can be evaluated on a more meaningful basis.

This article is intended for research, process-development and industrial technical reference only.